Abstract:

Objective: To improve the diagnosis and treatment of ovarian Sertoli-Leydig cell tumor (SLCT). Methods: Thirteen cases of ovarian SLCT admitted between June 2014 and July 2021 were analyzed retrospectively, including their clinical characteristics, diagnosis, treatment and prognosis. Results: The median age of onset was 31 years (13-72 years) in 13 patients. Eight patients (61.5%) had the androgenic manifestations (due to the elevated levels of testosterone), 3 patients (23.1%) presented with abnormal uterine bleeding, and the other two patients (15.4%) had no obvious clinical symptoms. Imaging mainly showed cystic-solid tumors or solid tumors. All 13 patients underwent surgery, and diagnosed with ovarian SLCT by histopathology and immunohistochemistry. Eleven patients were at stage ⅠA, and 2 patients at stage ⅠC. Four patients underwent the complementary surgery to resect the affected adnexa and perform the multi-point pelvic and abdominal biopsy after 1-2 months of the initial operation and histopathological diagnosis. Two patients with SLCT at stage ⅠC underwent postoperative chemotherapy with the bleomycin + etoposide + cisplatin (BEP) regimen. The median follow-up time after surgery was 33 months. None of the 13 patients had a recurrence. Conclusions: Ovarian SLCT should be considered when women had abnormal endocrine symptoms and ovarian cystic-solid or solid masses. Surgery is main treatment for SLCT patient, and operative and postoperative histopathology will confirm the diagnosis of ovarian SLCT. Postoperative chemotherapy can be accordingly considered, and the postoperative multidisciplinary follow-up has been suggested.

Key words: Ovarian tumors, Sertoli-Leydig cell tumor, Diagnosis, Therapy, Prognosis